Nicox
Nicox
ALCOX
EURONEXT
0.18
EUR
-37.93%
About
Nicox SA is a France-based international ophthalmic company. It is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients.
Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The Company has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis).
It has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 78.5K |
| Three Month Average Volume | 3.6M |
| High Low | |
| Fifty-Two Week High | 0.46495 EUR |
| Fifty-Two Week Low | 0.16 EUR |
| Fifty-Two Week High Date | 08 Feb 2024 |
| Fifty-Two Week Low Date | 06 Aug 2024 |
| Price and Volume | |
| Current Price | 0.1796 EUR |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | 1.59% |
| Thirteen Week Relative Price Change | -41.08% |
| Twenty-Six Week Relative Price Change | -51.85% |
| Fifty-Two Week Relative Price Change | -57.52% |
| Year-to-Date Relative Price Change | -57.54% |
| Price Change | |
| One Day Price Change | 0.00% |
| Thirteen Week Price Change | -43.75% |
| Twenty-Six Week Price Change | -53.69% |
| Five Day Price Change | -0.88% |
| Fifty-Two Week Price Change | -55.69% |
| Year-to-Date Price Change | -57.05% |
| Month-to-Date Price Change | -0.11% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 0.42947 EUR |
| Book Value Per Share (Most Recent Quarter) | 0.91276 EUR |
| Tangible Book Value Per Share (Last Fiscal Year) | 0.42899 EUR |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.24715 EUR |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -0.42798 EUR |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.13885 EUR |
| Revenue Per Share (Trailing Twelve Months) | 0.07533 EUR |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | 0 EUR |
| Dividend Per Share (Trailing Twelve Months) | 0 EUR |
| Dividend Per Share (5 Year) | 0 EUR |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.42 EUR |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.37207 EUR |
| Normalized (Last Fiscal Year) | -0.41821 EUR |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.42 EUR |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.37207 EUR |
| Including Extraordinary Items (Last Fiscal Year) | -0.42 EUR |
| Including Extraordinary Items (Trailing Twelve Months) | -0.37207 EUR |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 0.22581 EUR |
| Cash Per Share (Most Recent Quarter) | 0.38112 EUR |
| Cash Flow Per Share (Last Fiscal Year) | -0.34831 EUR |
| Cash Flow Per Share (Trailing Twelve Months) | -0.36087 EUR |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.44547 EUR |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -591 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -508.90% |
| Pretax Margin (Last Fiscal Year) | -309.42% |
| Pretax Margin (5 Year) | -359.33% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -256.57% |
| Operating Margin (Trailing Twelve Months) | -585.93% |
| Operating Margin (5 Year) | -299.80% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -302.49% |
| Net Profit Margin (Trailing Twelve Months) | -485.70% |
| Net Profit Margin (5 Year) | -337.85% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -35.42% |
| Tangible Book Value (5 Year) | 4.83% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | 21.19% |
| Revenue Growth (3 Year) | 11.38% |
| Revenue Change (Trailing Twelve Months) | -51.31% |
| Revenue Per Share Growth | 0.45% |
| Revenue Growth (5 Year) | -18.83% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | 212.06% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 66.54% |
| EPS Change (Trailing Twelve Months) | 69.98% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 2.1M |
| Net Debt (Last Fiscal Year) | 13.9M |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 2 |
| Price to Sales (Trailing Twelve Months) | 3 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | 0.00% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 0 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 117 |
| Long Term Debt to Equity (Most Recent Quarter) | 40 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 16 |
| Current Ratio (Most Recent Quarter) | 3 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -100,000 |
| Free Cash Flow (Trailing Twelve Months) | -21,135,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -20 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 117 |
| Total Debt to Equity (Most Recent Quarter) | 46 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -28.58% |
| Return on Assets (Trailing Twelve Months) | -19.13% |
| Return on Assets (5 Year) | -22.59% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -56.55% |
| Return on Equity (Trailing Twelve Months) | -32.68% |
| Return on Equity (5 Year) | -32.77% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -31.00% |
| Return on Investment (Trailing Twelve Months) | -21.35% |
| Return on Investment (5 Year) | -24.55% |